AVITA Medical, Inc. (RCEL): Results of Operations and Financial Condition
AVITA Medical, Inc. (RCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rcel-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven VALENCIA, Calif., August 6, 2026 (GLOBE NEWSWIRE) — AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a
How this was made
The 30-second read
Why it matters
Traders can update RCEL valuation inputs immediately using the raised 2026 revenue range and the company’s stated expectation to reach cash-flow breakeven in Q4 2026. The CMS proposed 2027 Medicare payment updates for RECELL add a potential reimbursement tailwind, but it is not final.
Market read
This is a primary-source earnings and guidance update with explicit cash-flow breakeven timing and a US reimbursement policy catalyst for RECELL.
What to watch
Cash balance and net cash use remain meaningful (cash use improved but still negative), and the credit facility tranche depends on trailing-twelve-month net revenue thresholds, which could constrain upside if execution slips.
Background
AVITA Medical filed an 8-K with Exhibit 99.1 reporting Q2 2026 financial results and updating full-year guidance, alongside commentary on RECELL reimbursement developments.
Ticker impact
AVITA Medical reports Q2 results, raises 2026 revenue guidance to $86M-$89M, and expects cash-flow breakeven in Q4 2026.
Near-term bias higher as traders reprice FY revenue expectations and the probability/timing of cash-flow breakeven; follow-through depends on how the market values the CMS proposal and upcoming PermeaDerm I data.
The filing includes fresh, decision-relevant numbers (Q2 revenue growth, raised full-year guidance range, and explicit Q4 cash-flow breakeven expectation) plus a concrete policy catalyst (CMS proposed 2027 Medicare payment updates for RECELL).
Market effects
Reinforces investor appetite for acute wound care and regenerative medicine names when reimbursement frameworks appear to be improving.
Limited direct regional read-through; international revenue growth is mentioned but the key policy catalyst is US Medicare.
Modest, since the reimbursement proposal is US-specific, though it can affect global commercialization expectations for RECELL.
Counterpoint
CMS rules are only proposed, and PermeaDerm I data is still pending; the guidance raise may already reflect known momentum, limiting upside beyond breakeven narrative.
Key entities
- issuerAVITA Medical, Inc.
NASDAQ-listed therapeutic acute wound care company reporting Q2 results and raising 2026 revenue guidance.
- productRECELL
AVITA’s skin cell suspension autograft product, the main revenue driver discussed in the filing.
- regulatorCenters for Medicare & Medicaid Services (CMS)
Proposed 2027 Medicare payment updates for RECELL-related procedures, if adopted.
- productPermeaDerm
Wound temporizer product; PermeaDerm I study data expected in August per the filing.
